ESR1 and breast neoplasm: Because anti-estrogen therapy targets ERα, which acts as a growth factor and is required for the proliferation of breast tumor cells, as expected, researchers have found loss of ERα expression to be an important factor in the acquisition of anti-estrogen therapy resistance.